Posts by: Magdalena Kegel

Magdalena Kegel

Magdalena is a writer with a passion for bridging the gap between the people performing research, and those who want or need to understand it. She writes about medical science and drug discovery. She holds an MS in Pharmaceutical Bioscience and a PhD — spanning the fields of psychiatry, immunology, and neuropharmacology — from Karolinska Institutet in Sweden.

July 14, 2017

Phase 3 Nintedanib-Chemo Combo Trial Recruits Mesothelioma Patients for Global Study

News

A Phase 3 trial is recruiting 450 participants at clinics worldwide to test whether nintedanib, used in combination with the standard chemotherapy drugs Alimta (pemetrexed) and Platinol (cisplatin) in patients with ... Read more

July 11, 2017July 11, 2017

Measles Virus May Be Ready Weapon to Turn Against Mesothelioma Cells

News

Certain strains of the measles virus could potentially be used to treat mesothelioma because the virus selectively targets a factor found on the surface of mesothelioma cells, researchers from the University of ... Read more

July 7, 2017

Combination of Immunotoxic Factors and Checkpoint Blocker Clears Mesothelioma in Mice, Study Reports

News

Combining mesothelioma-targeted therapies with one that prevents tumors from evading the immune system led to the eradication of mesothelioma in most mice involved in a study, researchers said. The mesothelioma-specific ... Read more

June 19, 2017June 19, 2017

Zoledronic Acid Could Be a Mesothelioma Add-On Treatment, Researchers Contend After Pilot Study

News

Zoledronic acid was only modestly active as a stand-alone therapy for advanced malignant pleural mesothelioma in a small Phase 2 pilot clinical trial. But researchers argue that its properties make ... Read more

June 16, 2017

TCR²’s Engineered Immune T-Cells Outperform More Common Class of Cells Against Mesothelioma, Studies Show

News

A key approach to treating cancer these days is engineering immune T-cells to produce receptors on their surfaces that recognize cancer, so that the T-cells can attack it. One engineering ... Read more

June 15, 2017June 15, 2017

Chemotherapy Effective in Peritoneal Mesothelioma, But Surgery Also Needs Evaluation, Researchers Say

News

Aggressive malignant peritoneal mesothelioma responds to treatment with Alimta (pemetrexed) and Platinol (cisplatin) chemotherapy, reports a study examining patient outcomes. But more studies are needed to compare chemo’s effectiveness to surgery ... Read more

June 14, 2017June 14, 2017

MicroRNAs Help Predict Pleural Mesothelioma Outcomes, European Study Finds

News

European researchers have identified two microRNAs, or small non-coding RNA molecules, that can be used to predict outcomes of malignant pleural mesothelioma, in an international study that aimed to clear up the ... Read more

May 31, 2017May 31, 2017

Tremelimumab, Imfinzi Combo Has Manageable Side Effects in Mesothelioma, Italian Trial Shows

News

It is safe for malignant mesothelioma patients to combine Tremelimumab and Imfinzi (durvalumab), according to a study to be presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, set ... Read more

May 23, 2017May 23, 2017

Yondelis Stabilized Mesothelioma in Many Patients Taking Part in Phase 2 Clinical Trial

News

Yondelis (trabectedin) stabilized a form of advanced mesothelioma that had progressed after earlier chemotherapy, according to a Phase 2 clinical trial in Italy. Researchers will present the trial’s findings at ... Read more

May 22, 2017May 22, 2017

Bristol-Myers Squibb Recruits Patients for Phase 3 Trial Testing Opdivo-Yervoy Combo to Treat MPM

News

Bristol-Myers Squibb is recruiting 600 participants into a global Phase 3 clinical trial investigating a combination of two immune checkpoint inhibitors — Opdivo (nivolumab) and Yervoy (ipilimumab) — in patients ... Read more